These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1094 related articles for article (PubMed ID: 34747643)

  • 21. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination.
    Abdul-Wahab Kadhum A; Rushdi Abdullah A; Mujahid A
    Arch Razi Inst; 2023 Jun; 78(3):1071-1075. PubMed ID: 38028836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immediate Adverse Reaction and SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG of COVID-19 Vaccines Among Health Staffs.
    Rasheed WS; Sarkees AN
    Disaster Med Public Health Prep; 2024 Apr; 18():e66. PubMed ID: 38618867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers.
    Rasheed WS; Sarkees AN
    Medicine (Baltimore); 2023 Oct; 102(40):e35444. PubMed ID: 37800839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).
    Stirrup O; Krutikov M; Tut G; Palmer T; Bone D; Bruton R; Fuller C; Azmi B; Lancaster T; Sylla P; Kaur N; Spalkova E; Bentley C; Amin U; Jadir A; Hulme S; Giddings R; Nacer-Laidi H; Baynton V; Irwin-Singer A; Hayward A; Moss P; Copas A; Shallcross L
    J Infect Dis; 2022 Nov; 226(11):1877-1881. PubMed ID: 35429382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
    Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine Type-, Age- and Past Infection-Dependence of the Humoral Response to SARS-CoV-2 Spike S Protein.
    Romero-Pinedo S; Quesada M; Horndler L; Álvarez-Fernández S; Olmo A; Abia D; Alarcón B; Delgado P
    Front Immunol; 2022; 13():809285. PubMed ID: 35296086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.
    Verstappen GM; de Wolff L; Arends S; Heiermann HM; van Sleen Y; Visser A; Terpstra JH; Diavatopoulos DA; van der Heiden M; Vissink A; van Baarle D; Kroese FGM; Bootsma H
    RMD Open; 2022 Apr; 8(1):. PubMed ID: 35414631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection.
    Gray AN; Martin-Blais R; Tobin NH; Wang Y; Brooker SL; Li F; Gadoth A; Elliott J; Faure-Kumar E; Halbrook M; Hofmann C; Kashani S; Kazan C; Yang OO; Fulcher JA; Grovit-Ferbas K; Rimoin AW; Aldrovandi GM
    PLoS One; 2021; 16(11):e0259703. PubMed ID: 34748607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
    Yürüker Ö; Yetkin O; Güvenir M
    Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
    Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus.
    Papaneophytou C; Nicolaou A; Pieri M; Nicolaidou V; Galatou E; Sarigiannis Y; Pantelidou M; Panayi P; Thoma T; Stavraki A; Argyrou X; Kalogiannis T; Yiannoukas K; Petrou CC; Felekkis K
    PLoS One; 2022; 17(6):e0269885. PubMed ID: 35696396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland.
    Brown AC; Koshute PT; Cowley HP; Robinette MS; Gravelyn SR; Patel SV; Ju EY; Frommer CT; Zambidis AE; Schneider EJ; Zhao MY; Mugo BK; Clarke W; Kruczynski K; Pisanic N; Heaney CD; Colella TA
    Microbiol Spectr; 2023 Aug; 11(4):e0276522. PubMed ID: 37289070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
    Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
    Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-Match.
    Mulleners SJ; Juncker HG; van Gils MJ; van Goudoever JB; van Keulen BJ
    J Hum Lact; 2022 Aug; 38(3):401-406. PubMed ID: 35726498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.